1. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)‏
by Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, and
Blood
Volume 116(19):
November 11, 2010
©2010 by American Society of Hematology

2. Median BCR-ABL (IS) transcript levels in substudy and nonsubstudy patients over 84 months.
Median BCR-ABL (IS) transcript levels in substudy and nonsubstudy patients over 84 months. Lines along x-axis connect medians over time; vertical bars represent 25th and 75th percentiles; vertical lines represent range.
Timothy P. Hughes et al. Blood 2010;116:
©2010 by American Society of Hematology

3. EFS at 6 (A), 12 (B), and 18-month (C) landmarks by molecular response.
EFS at 6 (A), 12 (B), and 18-month (C) landmarks by molecular response. These figures use the original EFS definition, without loss of CCyR counting as an event.
Timothy P. Hughes et al. Blood 2010;116:
©2010 by American Society of Hematology

4. Time to loss of CCyR at 18-month landmarks by molecular response.
Timothy P. Hughes et al. Blood 2010;116:
©2010 by American Society of Hematology

5. Time to AP/BC according to 6 (A), 12 (B), and 18-month (C) landmarks by molecular response.
Timothy P. Hughes et al. Blood 2010;116:
©2010 by American Society of Hematology